Parabilis GC discloses stock option holdings
Parabilis Medicines, Inc. General Counsel Teresa Jurgensen filed an initial ownership report showing holdings of stock options tied to the company’s common stock.
Rhea-AI Filing Summary
Parabilis Medicines, Inc. General Counsel Teresa Jurgensen filed an initial ownership report showing holdings of stock options tied to the company’s common stock. She holds options covering 162,453 shares at an exercise price of $3.14 per share expiring on February 17, 2036, and options covering 214,438 shares at $1.88 per share expiring on September 4, 2034. According to the vesting schedules, 25% of one grant vested on August 1, 2025 with the balance vesting in 36 monthly installments, while the other grant vests in 48 equal monthly installments beginning on February 9, 2026, subject to her continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Jurgensen Teresa
Role
General Counsel
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 376,891 contracts (Direct)
Footnotes (2)
- F1. 25% of the shares subject to this option vested and became exercisable on August 1, 2025 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- F2. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from February 9, 2026, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Underlying shares (grant 1): 162,453 shares
Exercise price (grant 1): $3.14 per share
Underlying shares (grant 2): 214,438 shares
+3 more
6 metrics
Underlying shares (grant 1)
162,453 shares
Stock option at $3.14 exercise price
Exercise price (grant 1)
$3.14 per share
Stock Option (right to buy), expires February 17, 2036
Underlying shares (grant 2)
214,438 shares
Stock option at $1.88 exercise price
Exercise price (grant 2)
$1.88 per share
Stock Option (right to buy), expires September 4, 2034
Vested portion (grant 1)
25% vested
Vested on August 1, 2025; balance over 36 months
Vesting period (grant 2)
48 monthly installments
Commencing February 9, 2026, subject to continued service
Key Terms
Stock Option (right to buy), exercise price, expiration date, vesting in monthly installments, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"exercisePrice: "3.1400" and "1.8800" as the exercise price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-02-17T00:00:00.000Z and 2034-09-04T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting in monthly installments financial
"vesting in thirty-six (36) equal monthly installments thereafter"
underlying common stock financial
"underlying_security_title: "Common Stock""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Parabilis Medicines (PBLS) General Counsel report in this Form 3?
Parabilis Medicines General Counsel Teresa Jurgensen reports her holdings of stock options linked to common shares. The filing lists option quantities, exercise prices, expiration dates, and vesting schedules, but does not show any recent buying or selling activity.
What are the exercise prices of the Parabilis Medicines (PBLS) options reported?
The reported stock options have exercise prices of $3.14 per share for one grant and $1.88 per share for the other. These prices represent the cost per share to acquire common stock if the options are exercised after vesting.
When do the Parabilis Medicines (PBLS) General Counsel’s options expire?
One option grant expires on February 17, 2036, and the other expires on September 4, 2034. These expiration dates define the latest possible dates by which vested options can be exercised under the terms of the grants.
How do the Parabilis Medicines (PBLS) option grants vest for the General Counsel?
For one grant, 25% of the options vested on August 1, 2025, with the remaining 75% vesting in 36 equal monthly installments. The second grant vests in 48 equal monthly installments starting February 9, 2026, contingent on continued service.
Does this Parabilis Medicines (PBLS) Form 3 show insider buying or selling?
The Form 3 primarily records existing stock option holdings and their terms, not new market trades. The summarized data show unknown transaction codes and no net share purchases or sales, indicating this filing is an initial ownership snapshot rather than a trade report.
AI-generated analysis. How Rhea-AI works. Not financial advice.
